21 Health Daily | NHC Promotes Medical Resource Redistribution; XtalPi Announces Main Board Listing Plan on HKEX
XtalPi
Computation-Driven Innovative Drug R&D Provider
Source: 21st Century Economic Report
China's National Health Commission: Promoting the下沉of Urban Medical Resources to County-Level Hospitals and Urban-Rural Grassroots
According to the website of the National Health Commission of China, in order to further improve the service capabilities of county-level hospitals and urban-rural grassroots medical and health institutions, and better meet the needs of the people for medical treatment, the National Health Commission of China, together with relevant departments, has conducted research and widely solicited opinions. On this basis, they have formulated the "Notice on Further Improving the Mechanism to Promote the Sinking of Urban Medical Resources to County-Level Hospitals and Urban-Rural Grassroots Levels" (hereinafter referred to as the "Notice").
The Notice is divided into six parts. (1) Deepening the work of urban hospitals supporting county-level hospitals. Local areas should combine the requirements of tertiary hospitals' targeted support for county-level hospitals and the "team-based" medical talent support work, make full use of existing cooperative relationships, and follow the principle of "overall planning and regional division". Urban tertiary hospitals within the province should be organized to support county-level hospitals, mainly in the form of "one-to-one" support with "one-to-many" as a supplement. This will enhance the management and service capabilities of county-level hospitals, accelerate the cultivation of professional talent teams, and improve the smooth functioning of two-way referral mechanisms.
(II) Organize urban hospitals to support community health service centers. Using the close-knit urban medical groups and specialty alliances laid out in a grid pattern as the vehicle, arrange for secondary-level and above urban hospitals to support community health service centers by conducting巡回诊疗 (mobile clinic services), teaching and training, enhancing service capabilities, promoting the下沉共享 (downward flow and sharing) of medical resources, establishing contact mechanisms, and supporting family doctor contract services.
(III) Deployment of hospitals at or above the county level to support township health centers and village clinics. Using closely-knit county-level medical consortia as a vehicle, organize urban secondary hospitals and county-level hospitals to provide tiered support to township health centers, and township health centers to support village clinics. Strengthen personnel deployment, innovate collaborative working models, and support the development of general practice departments and specialty departments at the grassroots level.
(IV) Carry out巡回医疗 in county, township, and village. Establish a 巡回医疗 system, organize urban 三级医院 to regularly conduct 巡回医疗 in counties and townships, 县(区)级医院 to regularly perform 巡回医疗 in townships and villages, and township health centers to be responsible for村级巡诊服务. Scientifically determine the frequency of 巡回医疗, and based on the actual needs of the assisted areas, provide disease diagnosis and treatment, health education and other services to increase the supply of basic medical and health services for rural residents. (V) Use information technology to connect medical institutions at all levels. Promote the unified operation and interconnection of information systems within medical consortia, and gradually achieve information sharing in medical services, public health services, medical security, and comprehensive management systems. Establish a remote medical service network covering provinces, cities, counties, towns, and villages, and promote the "grassroots examination, higher-level diagnosis" remote medical service model. Encourage the provision of internet-based medical services to enhance the accessibility and convenience of medical services. (6) Implementation. Local health administrative departments at all levels, traditional Chinese medicine (TCM) authorities, and disease control departments should strengthen organizational leadership, focus on incentives and constraints, reinforce assessment and evaluation, actively promote and publicize, to ensure the effective implementation of all measures.
Drug and Device Approval
NOCION Biotech's Anti-CD19 Monoclonal Antibody Proposed for Priority Review
China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) recently announced on its official website that the injectable Tafasitamab, submitted by InnoCare Pharma, is proposed for priority review. The indication is for use in combination with lenalidomide to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). Tafasitamab is a humanized monoclonal antibody targeting CD19 with an optimized Fc domain. AbbVie's Innovative ADC Therapy Proposed for Inclusion in Breakthrough Treatment Category
China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) recently announced that telisotuzumab vedotin, an infusion-ready sterile lyophilized powder submitted by AbbVie, is proposed for inclusion in the breakthrough therapy designation. It is intended for treating patients with c-Met protein overexpression, advanced/metastatic EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who experience disease progression during or after platinum-based therapy. Public data indicates that telisotuzumab vedotin (Teliso-V) is an investigational antibody-drug conjugate (ADC) targeting c-Met developed by AbbVie, utilizing the microtubule inhibitor MMAE as its cytotoxic payload. Potential Blockbuster Next-Gen GLP-1 Therapy Proposed for Breakthrough Treatment Designation China's National Medical Products Administration Center for Drug Evaluation (CDE) recently announced on its official website that Boehringer Ingelheim’s application for BI 456906 injection is proposed to be included in the breakthrough therapy designation for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH). Public information indicates that this is a GLP-1 receptor and glucagon (GCG) receptor dual agonist, survodutide, jointly developed by Boehringer Ingelheim and Zealand Pharma. The product was listed by Endpoints News as one of "five highly anticipated next-generation GLP-1 therapies." In February this year, the published Phase 2 trial results showed that 83% of MASH adult patients treated with this product achieved statistically significant improvement, compared to 18.2% in the placebo group. XtalPi Holdings Limited's drug candidate receives breakthrough therapy designation for treating crystalline retinopathy The official website of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration recently announced that ZVS101e Injection, submitted by Zhongyin Technology, is proposed to be included in the breakthrough therapy designation for the treatment of crystalline retinal degeneration. Public information shows that ZVS101e is a gene replacement therapy drug developed by Zhongyin Technology. It has previously been granted orphan drug designation by the U.S. FDA and received IND approval in both China and the United States. The drug has completed Phase 1/2 clinical trials and is about to enter Phase 3 clinical trials. In April this year, clinical trial data for the drug was published in a Nature sub-journal.
Capital Market
XtalPi Announces Plan to List on the Main Board of the Hong Kong Stock Exchange
QuantumPharm Inc. ("XtalPi", Stock Code: 2228.HK), an innovative R&D platform based on quantum physics, empowered by artificial intelligence and driven by robotics, announced its plan to list on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") on June 4.
QuantumPharm Inc. plans to globally offer 187,373,000 shares (subject to the exercise of the over-allotment option), of which 178,004,000 shares will be allocated for international offering (re-allocatable and subject to the exercise of the over-allotment option), and the remaining 9,369,000 shares will be allocated for Hong Kong offering (re-allocatable), at an issue price ranging from HKD 5.03 to HKD 6.03 per share.
Akeso Biopharma &Summit Expands Cooperation Area Scope On June 3, Akeso Biopharma announced that the company had signed a supplementary licensing agreement with Summit. Under the original collaboration and licensing agreement for the PD-1/VEGF bispecific antibody Ivonescimab, the licensing market scope for Ivonescimab has been expanded. According to the supplementary licensing agreement, Akeso Biopharma will receive a $70 million upfront payment and milestone payment, as well as sales royalties from the newly added licensed markets for Ivonescimab. Zhiwei Microbiology Completes RMB 100 Million Series A Financing Recently, Beijing BOE Zhimicro Technology Co., Ltd. (hereinafter referred to as "Zhimicro") announced the completion of its Series A financing, with a total financing amount reaching hundreds of millions of RMB. This round of financing was led byQingsong Capital Leads, Wuhe Investment, Yishan Company, and Pinfeng MedicalFollowed by senior industry investors. Reports show that the investors in this round have great confidence in the development prospects of Zhi Microbiology and will engage in deep cooperation to jointly build and expand the technology transformation and product development platform. They will also fully support and accelerate Zhi Microbiology's commercialization process both domestically and internationally, injecting strong momentum into its development, and continuously strengthening Zhi Microbiology's leading advantage in the POCT molecular diagnostics field.
Industry Highlights
Legend Biotech Releases First Clinical Data of "Cilta-cel" for Multiple Myeloma Patients
On June 3, local time in the United States, Legend Biotech announced for the first time the results of the Phase 2 study CARTITUDE-2 Cohort D of Cilta-cel (CARVYKTI) for patients with multiple myeloma.Data show that patients who did not achieve complete remission (CR) after frontline autologous stem cell transplantation can obtain deep and durable remission following a single infusion of ciltacabtagene autoleucel with or without lenalidomide maintenance therapy, with an overall response rate (ORR) reaching 94%.These data were shared as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and will be presented again orally at this year's European Hematology Association (EHA) Congress.
